Table 2.
Expression of pGSK-3α/βTyr279/216 in epithelial ovarian cancer and benign ovarian tumor
| Parameters | pGSK-3α/βTyr279/216 immunostaining
|
z | P-value | |||
|---|---|---|---|---|---|---|
| − | + | ++ | +++ | |||
| Benign or malignant | −4.759 | <0.001 | ||||
| Benign tumor (n=20) | 16 | 2 | 1 | 1 | ||
| EOC (n=71) | 11 | 22 | 14 | 24 | ||
| Age of EOC patient (years) | −0.685 | 0.508 | ||||
| ≤50 (n=38) | 8 | 10 | 8 | 12 | ||
| >50 (n=33) | 3 | 12 | 6 | 12 | ||
| Stage of EOC | −2.815 | 0.004 | ||||
| FIGO I + II (n=27) | 5 | 13 | 6 | 3 | ||
| FIGO III + IV (n=44) | 6 | 9 | 8 | 21 | ||
| Residual tumor of EOC | −2.005 | 0.044 | ||||
| ≤1 cm (n=53) | 10 | 18 | 10 | 15 | ||
| >1 cm (n=18) | 1 | 4 | 4 | 9 | ||
| Histological type of EOC | −1.518 | 0.132 | ||||
| Serous (n=39) | 5 | 9 | 10 | 15 | ||
| Other (n=32) | 6 | 13 | 4 | 9 | ||
| Histological grade of EOC | −0.298 | 0.791 | ||||
| Grade 1 (n=11) | 1 | 5 | 2 | 3 | ||
| Grade 2 + 3 (n=60) | 10 | 17 | 12 | 21 | ||
| Serum CA125 of EOC patient (U/mL) | −2.920 | 0.003 | ||||
| ≤500 (n=47) | 10 | 17 | 9 | 11 | ||
| >500 (n=24) | 1 | 5 | 5 | 13 | ||
| Chemotherapy response of EOC | −3.292 | 0.001 | ||||
| Response (n=55) | 10 | 20 | 13 | 12 | ||
| Nonresponse (n=16) | 1 | 2 | 1 | 12 | ||
Abbreviations: CA125, cancer antigen 125; EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics; GSK, glycogen synthase kinase.